JP2018502575A - 網膜色素上皮細胞集団の評価法 - Google Patents

網膜色素上皮細胞集団の評価法 Download PDF

Info

Publication number
JP2018502575A
JP2018502575A JP2017535832A JP2017535832A JP2018502575A JP 2018502575 A JP2018502575 A JP 2018502575A JP 2017535832 A JP2017535832 A JP 2017535832A JP 2017535832 A JP2017535832 A JP 2017535832A JP 2018502575 A JP2018502575 A JP 2018502575A
Authority
JP
Japan
Prior art keywords
cells
rpe
cell
differentiation
tgfβ
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017535832A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018502575A5 (enExample
Inventor
オスナット ボハナ−カシュタン
オスナット ボハナ−カシュタン
ベルメイカー リオル アン ローゼンベルグ
ベルメイカー リオル アン ローゼンベルグ
オフェル ウィセル
オフェル ウィセル
Original Assignee
セル キュア ニューロサイエンシズ リミテッド
セル キュア ニューロサイエンシズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55305031&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2018502575(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by セル キュア ニューロサイエンシズ リミテッド, セル キュア ニューロサイエンシズ リミテッド filed Critical セル キュア ニューロサイエンシズ リミテッド
Publication of JP2018502575A publication Critical patent/JP2018502575A/ja
Publication of JP2018502575A5 publication Critical patent/JP2018502575A5/ja
Priority to JP2021020986A priority Critical patent/JP7723482B2/ja
Priority to JP2025084549A priority patent/JP2025118972A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1323—Adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/54—Collagen; Gelatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
JP2017535832A 2014-12-30 2015-12-30 網膜色素上皮細胞集団の評価法 Pending JP2018502575A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021020986A JP7723482B2 (ja) 2014-12-30 2021-02-12 網膜色素上皮細胞集団の評価法
JP2025084549A JP2025118972A (ja) 2014-12-30 2025-05-21 網膜色素上皮細胞集団の評価法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462097753P 2014-12-30 2014-12-30
US62/097,753 2014-12-30
US201562116980P 2015-02-17 2015-02-17
US62/116,980 2015-02-17
US201562195304P 2015-07-22 2015-07-22
US62/195,304 2015-07-22
PCT/IL2015/051270 WO2016108240A1 (en) 2014-12-30 2015-12-30 Assessing retinal pigment epithelial cell populations

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2020085170A Division JP2020146044A (ja) 2014-12-30 2020-05-14 網膜色素上皮細胞集団の評価法
JP2021020986A Division JP7723482B2 (ja) 2014-12-30 2021-02-12 網膜色素上皮細胞集団の評価法

Publications (2)

Publication Number Publication Date
JP2018502575A true JP2018502575A (ja) 2018-02-01
JP2018502575A5 JP2018502575A5 (enExample) 2019-02-14

Family

ID=55305031

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2017535832A Pending JP2018502575A (ja) 2014-12-30 2015-12-30 網膜色素上皮細胞集団の評価法
JP2020085170A Pending JP2020146044A (ja) 2014-12-30 2020-05-14 網膜色素上皮細胞集団の評価法
JP2021020986A Active JP7723482B2 (ja) 2014-12-30 2021-02-12 網膜色素上皮細胞集団の評価法
JP2023038688A Pending JP2023078266A (ja) 2014-12-30 2023-03-13 網膜色素上皮細胞集団の評価法
JP2025084549A Pending JP2025118972A (ja) 2014-12-30 2025-05-21 網膜色素上皮細胞集団の評価法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2020085170A Pending JP2020146044A (ja) 2014-12-30 2020-05-14 網膜色素上皮細胞集団の評価法
JP2021020986A Active JP7723482B2 (ja) 2014-12-30 2021-02-12 網膜色素上皮細胞集団の評価法
JP2023038688A Pending JP2023078266A (ja) 2014-12-30 2023-03-13 網膜色素上皮細胞集団の評価法
JP2025084549A Pending JP2025118972A (ja) 2014-12-30 2025-05-21 網膜色素上皮細胞集団の評価法

Country Status (8)

Country Link
US (2) US20180011092A1 (enExample)
EP (2) EP3916085A1 (enExample)
JP (5) JP2018502575A (enExample)
AU (3) AU2015373051B2 (enExample)
CA (1) CA2972580A1 (enExample)
ES (1) ES2880346T3 (enExample)
IL (2) IL314417A (enExample)
WO (1) WO2016108240A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018525986A (ja) * 2015-07-29 2018-09-13 ハダシット メディカル リサーチ サービシーズ アンド ディベロップメント リミテッド 網膜色素上皮細胞の大規模生産

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL253244B2 (en) 2014-12-30 2023-09-01 Cell Cure Neurosciences Ltd Methods for treating retinal diseases
IL273405B2 (en) 2014-12-30 2024-01-01 Cell Cure Neurosciences Ltd Rpe cell populations and methods of generating same
CA2993912A1 (en) * 2015-08-05 2017-02-09 Cell Cure Neurosciences Ltd. Preparation of retinal pigment epithelium cells
WO2017021972A1 (en) * 2015-08-05 2017-02-09 Cell Cure Neurosciences Ltd. Preparation of photoreceptors for the treatment of retinal diseases
MY198362A (en) * 2017-06-23 2023-08-28 Zhuhai Essex Bio Pharmaceutical Co Ltd Method for Producing Soluble Recombinant Human-Basic Fibroblast Growth Factor (Rh-Bfgf)
WO2023009676A1 (en) * 2021-07-28 2023-02-02 Lineage Cell Therapeutics, Inc. Expansion of retinal pigment epithelium cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008017840A (ja) * 2006-06-26 2008-01-31 Millipore Corp 胚性幹細胞の成長
JP2010524457A (ja) * 2007-04-18 2010-07-22 ハダシット メディカル リサーチ サーヴィシーズ アンド ディヴェロップメント リミテッド 幹細胞に由来する網膜色素上皮細胞
US20130196369A1 (en) * 2012-02-01 2013-08-01 University Of Southern California Methods of Culturing Retinal Pigmented Epithelium Cells, Including Xeno-Free Production, RPE Enrichment, and Cryopreservation

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
SG49267A1 (en) 1989-08-14 1998-05-18 Photogenesis Inc Surgical instrument and cell isolation and transplantation
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US6045791A (en) 1992-03-06 2000-04-04 Photogenesis, Inc. Retinal pigment epithelium transplantation
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5755785A (en) 1994-08-12 1998-05-26 The University Of South Florida Sutureless corneal transplantation method
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5941250A (en) 1996-11-21 1999-08-24 University Of Louisville Research Foundation Inc. Retinal tissue implantation method
GB9715584D0 (en) 1997-07-23 1997-10-01 Eisai Co Ltd Compounds
GB0001930D0 (en) 2000-01-27 2000-03-22 Novartis Ag Organic compounds
OA12540A (en) 2001-01-31 2006-06-05 Pfizer Prod Inc Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes.
WO2003068233A1 (en) 2002-02-11 2003-08-21 Pfizer Limited Nicotinamide derivatives and a tiotropium salt in combination for the treatment of e.g. inflammatory, allergic and respiratory diseases
US7288658B2 (en) 2003-07-15 2007-10-30 Hoffmann-La Roche Inc. Process for preparation of pyridine derivatives
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
EP1799810A2 (en) 2004-10-12 2007-06-27 Technion Research & Development Foundation Ltd. Isolated primate embryonic cells and methods of generating and using same
US20090104695A1 (en) 2004-12-29 2009-04-23 Etti Ben Shushan Stem Cells Culture Systems
US9133435B2 (en) 2007-01-18 2015-09-15 Riken Method for induction/differentiation into photoreceptor cell
US20090226955A1 (en) * 2007-12-21 2009-09-10 University Of Miami Immortalized retinal pigmented epithelial cells
US10485829B2 (en) 2009-11-17 2019-11-26 Astellas Institute For Regenerative Medicine Methods of producing human RPE cells and pharmaceutical preparations of human RPE cells
US20120258451A1 (en) 2011-04-08 2012-10-11 Advanced Cell Technology, Inc. Laser isolation of viable cells
IL320536A (en) 2011-11-14 2025-06-01 Astellas Inst For Regenerative Medicine Pharmaceutical preparations of human RPE cells and their use
CA2863172C (en) 2012-01-31 2022-05-03 Cell Cure Neurosciences Ltd. Methods of selecting retinal pigmented epithelial cells
CN102618497B (zh) * 2012-03-15 2013-10-02 中国人民解放军第三军医大学第一附属医院 利用人骨髓间充质干细胞制备视网膜色素上皮细胞的方法
US9458428B2 (en) 2012-06-05 2016-10-04 The Regents Of The University Of California Methods and compositions for the rapid production of retinal pigmented epithelial cells from pluripotent cells
AU2014212230B2 (en) 2013-02-01 2019-07-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for generating retinal pigment epithelium (RPE) cells from induced pluripotent stem cells (iPSCs)
WO2015087231A1 (en) * 2013-12-11 2015-06-18 Pfizer Limited Method for producing retinal pigment epithelial cells
US20150159134A1 (en) * 2013-12-11 2015-06-11 Pfizer Limited Method for producing retinal pigment epithelial cells
WO2015175504A1 (en) * 2014-05-12 2015-11-19 The Johns Hopkins University Differentiation of human pluripotent stem cells into retinal pigment epithelium using hif1 inhibitors
IL273405B2 (en) 2014-12-30 2024-01-01 Cell Cure Neurosciences Ltd Rpe cell populations and methods of generating same
IL253244B2 (en) 2014-12-30 2023-09-01 Cell Cure Neurosciences Ltd Methods for treating retinal diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008017840A (ja) * 2006-06-26 2008-01-31 Millipore Corp 胚性幹細胞の成長
JP2010524457A (ja) * 2007-04-18 2010-07-22 ハダシット メディカル リサーチ サーヴィシーズ アンド ディヴェロップメント リミテッド 幹細胞に由来する網膜色素上皮細胞
US20130196369A1 (en) * 2012-02-01 2013-08-01 University Of Southern California Methods of Culturing Retinal Pigmented Epithelium Cells, Including Xeno-Free Production, RPE Enrichment, and Cryopreservation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CELL STEM CELL (2009) VOL.5, PP.396-408, JPN5017010931, ISSN: 0004366029 *
JOURNAL OF BIOLOGICAL CHEMISTRY (2010) VOL.285, NO.35, PP.26933-26944, JPN6019044063, ISSN: 0004366027 *
MOLECULAR VISION (2011) VOL.17, PP.558-575, JPN6019044061, ISSN: 0004366026 *
PLOS ONE (2012) VOL.7, NO.6, E35325, PP.1-16, JPN6019044065, ISSN: 0004366028 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018525986A (ja) * 2015-07-29 2018-09-13 ハダシット メディカル リサーチ サービシーズ アンド ディベロップメント リミテッド 網膜色素上皮細胞の大規模生産
US11230696B2 (en) 2015-07-29 2022-01-25 Hadasit Medical Research Services And Development Ltd. Large scale production of retinal pigment epithelial cells
JP7055095B2 (ja) 2015-07-29 2022-04-15 ハダシット メディカル リサーチ サービシーズ アンド ディベロップメント リミテッド 網膜色素上皮細胞の大規模生産

Also Published As

Publication number Publication date
AU2015373051A1 (en) 2017-07-13
US20230051803A1 (en) 2023-02-16
JP7723482B2 (ja) 2025-08-14
JP2021078513A (ja) 2021-05-27
CA2972580A1 (en) 2016-07-07
AU2015373051B2 (en) 2022-10-06
EP3240890B1 (en) 2021-06-16
AU2023200036B2 (en) 2025-08-07
IL253242A0 (en) 2017-08-31
IL314417A (en) 2024-09-01
JP2025118972A (ja) 2025-08-13
ES2880346T3 (es) 2021-11-24
AU2025260003A1 (en) 2025-11-20
WO2016108240A1 (en) 2016-07-07
US20180011092A1 (en) 2018-01-11
JP2020146044A (ja) 2020-09-17
EP3240890A1 (en) 2017-11-08
AU2023200036A1 (en) 2023-02-09
JP2023078266A (ja) 2023-06-06
EP3916085A1 (en) 2021-12-01

Similar Documents

Publication Publication Date Title
JP7608192B2 (ja) Ｒｐｅ細胞集団およびそれを作製する方法
JP7723482B2 (ja) 網膜色素上皮細胞集団の評価法
HK40063422A (en) Assessing retinal pigment epithelial cell populations
NZ733006A (en) Rpe cell populations and methods of generating same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190104

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190104

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200514

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201014